TY - JOUR
T1 - Nrf2
T2 - The Master and Captain of Beta Cell Fate
AU - Baumel-Alterzon, Sharon
AU - Katz, Liora S.
AU - Brill, Gabriel
AU - Garcia-Ocaña, Adolfo
AU - Scott, Donald K.
N1 - Funding Information:
This work was supported in part by grants from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases ( DK-020541 , DK-113079 , DK-105015 , DK-077096 , DK-110156 , DK-114338 , DK-104211 , and DK-116873 ), the American Diabetes Association ( 1-17-IBS-116 ), JDRF ( 1-INO-2016-212-A-N ), and a Mindich Child Health and Development Institute Pilot and Feasibility Grant .
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2021/1
Y1 - 2021/1
N2 - Prolonged hyperglycemia is toxic to pancreatic β cells, generating excessive reactive oxygen species, defective glucose-stimulated insulin secretion, decreased insulin production, and eventually β cell death and diabetes. Nrf2 is a master regulator of cellular responses to counteract dangerous levels of oxidative stress. Maintenance of β cell mass depends on Nrf2 to promote the survival, function, and proliferation of β cells. Indeed, Nrf2 activation decreases inflammation, increases insulin sensitivity, reduces body weight, and preserves β cell mass. Therefore, numerous pharmacological activators of Nrf2 are being tested in clinical trials for the treatment of diabetes and diabetic complications. Modulating Nrf2 activity in β cells is a promising therapeutic approach for the treatment of diabetes.
AB - Prolonged hyperglycemia is toxic to pancreatic β cells, generating excessive reactive oxygen species, defective glucose-stimulated insulin secretion, decreased insulin production, and eventually β cell death and diabetes. Nrf2 is a master regulator of cellular responses to counteract dangerous levels of oxidative stress. Maintenance of β cell mass depends on Nrf2 to promote the survival, function, and proliferation of β cells. Indeed, Nrf2 activation decreases inflammation, increases insulin sensitivity, reduces body weight, and preserves β cell mass. Therefore, numerous pharmacological activators of Nrf2 are being tested in clinical trials for the treatment of diabetes and diabetic complications. Modulating Nrf2 activity in β cells is a promising therapeutic approach for the treatment of diabetes.
KW - Nrf2
KW - diabetes
KW - metabolic stress
KW - oxidative stress
KW - pancreatic beta cell
KW - proliferation
UR - http://www.scopus.com/inward/record.url?scp=85096906481&partnerID=8YFLogxK
U2 - 10.1016/j.tem.2020.11.002
DO - 10.1016/j.tem.2020.11.002
M3 - Review article
C2 - 33243626
AN - SCOPUS:85096906481
SN - 1043-2760
VL - 32
SP - 7
EP - 19
JO - Trends in Endocrinology and Metabolism
JF - Trends in Endocrinology and Metabolism
IS - 1
ER -